Eli Lilly Reports Breakthrough Phase 3 Jaypirca Results
Indianapolis, Indiana | April 13, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Indianapolis, Indiana | April 13, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3...
Paris, March 2, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug...
Dateline — WALTHAM, Mass., November 11, 2025:Zenas BioPharma, Inc. (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company dedicated to developing...
INDIANAPOLIS, September 8, 2025 — Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, has demonstrated a...
Imbed Biosciences has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE)...
The FDA has approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax for the 2025-2026 season, targeting high-risk groups....
The FDA approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax while ending broad Emergency Use Authorization. Eligibility is...
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Gilgamesh Pharmaceuticals’ lead investigational candidate bretisilocin (GM-2505), a next-generation...
PharmaTher Holdings Ltd. announced FDA approval of KETARxâ„¢, its ketamine product for anesthesia and sedation, marking a significant milestone...
Terumo Corporation is acquiring UK-based OrganOx Limited for approximately USD 1.5 billion, enhancing its entry into the organ transplantation...
